Sarah Karlovitch

The addition of trastuzumab to chemotherapy for the treatment of early-stage, HER2-positive breast cancer helps to reduce disease recurrence and can potentially reduce the mortality from breast cancer by a third worldwide.

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.